Kura Oncology develops precision cancer medicines, with a focus on genetically defined blood cancers and solid tumors. Its best-known programs include menin inhibitors designed for acute myeloid leukemia (AML) and other cancers driven by specific genetic alterations such as NPM1 or KMT2A. The company partners and co-develops assets to advance late-stage clinical programs toward regulatory approval. Its customers, if products reach market, would be hematologists, oncologists and hospital systems treating genetically stratified patients.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 15.3 | — | -66.1 | — |
| Q3 2025 | 20.8 | — | -74.1 | — |
| Q4 2025 | 17.3 | — | -81 | — |
| Q1 2026 | 18.3 | — | -73.3 | — |
| Q2 2026 | 20.9 | 36.5% | -68.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Playtika Holding Corp. (PLTK), SpyGlass Pharma, Inc. (SGP), Corvus Pharmaceuticals, Inc. (CRVS), World Acceptance Corporation (WRLD), Ardelyx, Inc. (ARDX), Service Properties Trust (SVC)